Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Autor: Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J 2nd, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM, Treon, Steven P, Ioakimidis, Leukothea, Soumerai, Jacob D, Patterson, Christopher J

Publikováno v: Journal of Clinical Oncology; 8/10/2009, Vol. 27 Issue 23, p3830-3835, 6p

Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL.

Autor: Soumerai JD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Barrientos JC; Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida, United States., Ahn IE; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Coombs CC; University of California Irvine, San Diego, California, United States., Gladstone DE; Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, United States., Hoffmann MS; University of Kansas Medical Center, Westwood, Kansas, United States., Kittai AS; Mount Sinai Tisch Cancer Center, New York, NY, United States., Jacobs RW; Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States., Lipsky A; Columbia University Medical Center, New York, New York, United States., Patel K; Swedish Cancer Institute, Sweden., Rhodes JM; Rutgers/CINJ, New Brunswick, New Jersey, United States., Skarbnik AP; Novant Health, Charlotte, North Carolina, United States., Thompson MC; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Ermann DA; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States., Reville PK; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Shah HR; Huntsman Cancer Institute, Salt Lake City, Utah, United States., Brown JR; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Stephens DM; University of North Carolina, Chapel Hill, North Carolina, United States.

Publikováno v: Blood advances [Blood Adv] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis.

Autor: Kaulen LD; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany., Karschnia P; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Neurosurgery, Ludwig Maximilians University (LMU), Munich, Germany.; Department of Neurosurgery, Friedrich-Alexander-University Erlangen/Nuernberg, Erlangen, Germany., Doubrovinskaia S; Department of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany., Abramson JS; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Martinez-Lage M; Department of Pathology, Division of Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Shankar G; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Choi BD; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Barnes JA; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., El-Jawahri A; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Hochberg EP; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Johnson PC; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Soumerai JD; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Wick W; Department of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany., Maus MV; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Chen YB; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Frigault MJ; Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Dietrich J; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Dec; Vol. 99 (12), pp. 2411-2415. Date of Electronic Publication: 2024 Oct 23.

Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.

Autor: Nemec R; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Scherrer-Crosbie M; Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Abramson JS; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Redd R; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA., Gilman HK; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA., Ho T; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA., Wu J; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA., Heemelaar J; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA., Neuberg D; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA., Hochberg EP; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Barnes JA; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobsen ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Friedman RS; Division of Medical Oncology, Newton-Wellesley Hospital, Newton, MA, USA., LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Neilan TG; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA., Soumerai JD; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2024 Jun; Vol. 65 (6), pp. 783-788. Date of Electronic Publication: 2024 Feb 21.

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.

Autor: Soumerai JD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Diefenbach CS; Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA., Asch A; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Kumar A; University of Arizona, Tucson, Arizona, USA., Tsai ML; Swedish Cancer Institute, Seattle, Washington, USA., Jandl TA; Stony Brook University Hospital, Stony Brook, New York, USA., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA., Kenkre VP; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA., Awan F; University of Texas Southwestern Medical Center, Dallas, Texas, USA., Novotny W; BeiGene, LTD, Cambridge, Massachusetts, USA., Huang J; BeiGene, LTD, Cambridge, Massachusetts, USA., Miao L; MEI Pharma, Inc., San Diego, California, USA., Rajagopalan P; PR Consulting, Mountain Lakes, New Jersey, USA., Ghalie RG; MEI Pharma, Inc., San Diego, California, USA., Zelenetz AD; Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1762-1770. Date of Electronic Publication: 2024 Mar 19.